(Q38260179)

1 September 2017

1 reference

title

Targeting interleukin-1 in heart failure and inflammatory heart disease (English)

1 reference

1 September 2017

0 references

0 references

0 references

Benjamin W Van Tassell

series ordinal

1

1 reference

1 September 2017

Juan M Valle Raleigh

series ordinal

2

1 reference

1 September 2017

Antonio Abbate

series ordinal

3

1 reference

1 September 2017

language of work or name

1 reference

1 February 2015

1 reference

Current heart failure reports

1 September 2017

published in

1 reference

1 September 2017

volume

12

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

33-41

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

1 September 2017

1 reference

Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

The pathophysiology of heart failure with preserved ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Inflammatory mediators and the failing heart: past, present, and the foreseeable future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

The inflammatory response in myocardial injury, repair, and remodelling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Inflammatory mediators in chronic heart failure: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Systemic inflammation in heart failure--the whys and wherefores

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

C-reactive protein and other inflammatory risk markers in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Targeting interleukin-1 in heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Interleukin-1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Formation of the inflammasome in acute myocarditis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Interleukin 1 or tumor necrosis factor can promote Coxsackie B3-induced myocarditis in resistant B10.A mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Interleukin-1β induces a reversible cardiomyopathy in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Interleukin-18 mediates interleukin-1-induced cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Induction of nitric oxide synthase gene by interleukin-1 beta in cultured rat cardiocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

High-sensitivity C-reactive protein and parameters of left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Predictive value of high sensitivity CRP in patients with diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11897-014-0231-7

Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis

21 January 2018

1 reference

12 December 2020

Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity

1 reference

12 December 2020

Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)

1 reference

12 December 2020

G protein-mediated suppression of L-type Ca2+ current by interleukin-1 beta in cultured rat ventricular myocytes

1 reference

12 December 2020

Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution?

1 reference

12 December 2020

Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro.

1 reference

12 December 2020

Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension

1 reference

12 December 2020

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

1 reference

12 December 2020

Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes

1 reference

12 December 2020

Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis.

1 reference

12 December 2020

Suppression of beta-adrenergic responsiveness of L-type Ca2+ current by IL-1beta in rat ventricular myocytes.

1 reference

12 December 2020

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study

1 reference

12 December 2020

Involvement of ceramide in inhibitory effect of IL-1 beta on L-type Ca2+ current in adult rat ventricular myocytes

1 reference

12 December 2020

10.1007/S11897-014-0231-7

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1019378698

0 references

1 reference